Option chain shows key data for LENZ Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for LENZ Therapeutics.

LENZ Therapeutics (NASDAQ:LENZ) Stock, Option Chain

LENZ Therapeutics

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

Eyes

Analyst Color

Biotech

Equities

News

Health Care

Reiteration

Analyst Ratings

Trading Ideas

General

LENZ

LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.

LENZ Therapeutics&#39; Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

movers image

Pre-Market Outlook

Movers

ADSE

ARBB

EONR

HCTI

IBRX

INDO

JFBR

JTAI

LGVN

MNPR

NWTN

PXDT

TARS

TCBP

TVGN

UPXI

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

vaccine-4892059

Lenz Therapeutics shares hit a new 52-week high during Monday&#39;s session. The company announced the FDA accepted its new drug application.

Why LENZ Therapeutics Stock Hit A New 52-Week High Today

LENZ Therapeutics Inc

LENZING AG U/ADR by Lenzing AG

Lenzing AG

Press Releases

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

Earnings

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZ Therapeutics to Host Commercial Day on April 15, 2025

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

ABOS

AnaptysBio

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Chimerix

Cogent Biosciences

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Organogenesis Holdings

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Relay Therapeutics

Sana Biotechnology

Sionna Therapeutics

Tyra Biosciences

Valneva

Verve Therapeutics

Zymeworks

HC Wainwright & Co.

Raymond James

Piper Sandler

Leerink Partners

Citigroup

Comments

LENZ Therapeutics

LENZ Therapeutics (LENZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga